MARKET

TTNP

TTNP

Titan Pharmaceut
NASDAQ
6.42
-0.30
-4.48%
After Hours: 6.79 +0.37 +5.81% 16:15 05/24 EDT
OPEN
6.48
PREV CLOSE
6.72
HIGH
6.48
LOW
6.39
VOLUME
1.59K
TURNOVER
0
52 WEEK HIGH
16.60
52 WEEK LOW
5.00
MARKET CAP
5.87M
P/E (TTM)
-1.0007
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TTNP last week (0513-0517)?
Weekly Report · 6d ago
Earnings week ahead: NVIDIA, Target, Zoom Video, Snowflake and more
Seeking Alpha · 05/19 12:02
TTNP Stock Earnings: Titan Pharmaceuticals Reported Results for Q4 2023
Titan Pharmaceuticals just reported results for the fourth quarter of 2023. The company did not report any revenue for the quarter. Titan Pharmaceuticals reported earnings per share of -5 cents and no revenue. The company reported no earnings for the third quarter of 2018.
Investorplace · 05/16 12:54
TTNP Stock Earnings: Titan Pharmaceuticals Reported Results for Q1 2024
Investorplace · 05/16 11:53
Financial Report: Q1 2024 - US-GAAP and TTNP Analysis
Press release · 05/16 09:05
Titan Pharmaceuticals: Q1 Earnings Snapshot
Barchart · 05/15 17:59
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers CareCloud stock moved upwards by to $ during Monday's regular session. Novavax stock rose   to $ after their, Q1 earnings came out yesterday. The company's market cap stands at $ billion. Losers TransCode Therapeutics and Applied DNA Sciences also declined.
Benzinga · 05/13 16:31
Weekly Report: what happened at TTNP last week (0506-0510)?
Weekly Report · 05/13 10:55
More
About TTNP
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Webull offers Titan Pharmaceuticals Inc stock information, including NASDAQ: TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.